[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613246":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":38,"centralContacts":42,"locations":48,"responsibleParty":69,"collaborators":71,"id":97,"slug":98,"hasResults":99,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":99,"sex":105,"minAge":106,"maxAge":10,"enrollmentInfo":107,"targetDuration":10,"studyType":110,"phases":10,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":124,"whyStopped":10,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},{"fullName":5,"class":6},"Imperial College London","OTHER",[8,14,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Hospital based follow up",null,"Exclusively hospital led follow up, face-to-face or remotely by the specialist treating team.",[13],"Other: Hospital based follow up",{"label":15,"type":10,"description":16,"interventionNames":17},"Primary care based follow up","After the initial hospital follow up, patients are discharged and exclusively managed by (non-specialist) general practices (GP or nurse led) in face-to-face or remote appointments, with hospital referral as necessary.",[18],"Other: Primary care based follow up",{"label":20,"type":10,"description":21,"interventionNames":22},"Planned shared care follow up","An ongoing combination of general practice and hospital management",[23],"Other: Planned shared care follow up",{"label":25,"type":10,"description":26,"interventionNames":27},"Self-management","After initial hospital follow up, patients are discharged and managed remotely, with no scheduled review. A tracking system monitors prostate-specific antigen (PSA) tests performed in primary care or secondary care. Patients access support workers for remote consultation to discuss symptoms and request further specialist management as required.",[28],"Other: Self-management",[30,32,34,36],{"type":6,"name":9,"description":11,"armGroupLabels":31,"otherNames":10},[9],{"type":6,"name":15,"description":16,"armGroupLabels":33,"otherNames":10},[15],{"type":6,"name":20,"description":21,"armGroupLabels":35,"otherNames":10},[20],{"type":6,"name":25,"description":26,"armGroupLabels":37,"otherNames":10},[25],[39],{"name":40,"affiliation":5,"role":41},"Rakesh Heer, BMed Sci MB BS MRCS PhD FRCS","PRINCIPAL_INVESTIGATOR",[43],{"name":44,"role":45,"phone":46,"phoneExt":10,"email":47},"Diana Johnson, BSc (Hon)","CONTACT","+44 (0) 1224 438144","followup@abdn.ac.uk",[49],{"facility":50,"status":10,"city":51,"state":10,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"London School of Hygiene & Tropical Medicine","London","WC1E 7HT","United Kingdom","UK",{"type":56,"coordinates":57},"Point",[58,59],-0.12574,51.50853,{"lat":59,"lon":58},[62,65,67],{"name":63,"role":45,"phone":64,"phoneExt":10,"email":47},"Diana Johnson","+44 (0) 1224438144",{"name":66,"role":41,"phone":10,"phoneExt":10,"email":10},"Linda Sharples",{"name":68,"role":41,"phone":10,"phoneExt":10,"email":10},"Luke Vale",{"type":70,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[72,74,76,78,80,82,84,86,88,90,93,95],{"name":73,"class":6},"London School of Hygiene and Tropical Medicine",{"name":75,"class":6},"University of Aberdeen",{"name":77,"class":6},"University of Leeds",{"name":79,"class":6},"Cardiff University",{"name":81,"class":6},"University of Sheffield",{"name":83,"class":6},"University of Southampton",{"name":85,"class":6},"University College, London",{"name":87,"class":6},"Royal Marsden NHS Foundation Trust",{"name":89,"class":6},"North Bristol NHS Trust",{"name":91,"class":92},"Cardiff and Vale University Health Board","OTHER_GOV",{"name":94,"class":92},"Liverpool University Hospitals NHS Foundation Trust",{"name":96,"class":92},"National Institute for Health Research, United Kingdom","100613246","identifying-the-best-follow-up-approach-for-people-who-have-had-treatment-to-cure-newly-diagnosed-prostate-cancer-100613246",false,"NCT07264088","Identifying the Best Follow up Approach for People Who Have Had Treatment to Cure Newly Diagnosed Prostate Cancer","The FOLLOW UP Study - a Natural Experiment Estimating the Clinical and Cost-effectiveness of Follow up Strategies After Curative Treatment for Prostate Cancer","FOLLOW-UP","Inclusion criteria:\n\nAll hospitals in England that provide radical prostatectomy or radical radiotherapy or focal therapy for prostate cancer and are identified by clinicians as receiving one of the four follow up strategies of interest will be eligible for inclusion in the study.\n\nIndividual patients satisfying the following criteria will be eligible for inclusion:\n\n* Having newly-diagnosed non-metastatic, clinically localised prostate cancer (ICD-10 code C61) in the Cancer Registry between 1 January 2018 and 31 December 2023;\n* Age 18 or over at diagnosis;\n* Completed primary curative treatment at an eligible hospital between 1 January 2019 and 31 December 2023 with either: radical radiotherapy +\u002F- hormones, or radical prostatectomy with curative intent +\u002F- lymphadenectomy, or focal therapy, in keeping with local practice;\n* Alive with no disease progression or metastasis 6 months after the date of completion of primary curative treatment.\n\nExclusion criteria:\n\n* Men who are treated for metastatic cancer; or receiving palliative prostate cancer care;\n* Men who have opted out of their data being used as part of national routine data sets will be excluded (https:\u002F\u002Fdigital.nhs.uk\u002Fservices\u002Fnational-data-opt-out).\n\nRecruitment to the survey component of the study will be limited to a sub-cohort of eligible participants that additionally meet the following criteria:\n\n* Alive;\n* Have achieved between three to four and a half years of follow up (from completion of initial curative treatment) during the survey period.","MALE","18 Years",{"count":108,"type":109},100000,"ESTIMATED","OBSERVATIONAL","Over 20,000 patients a year in the UK get surgery or radiotherapy to cure their prostate cancer. These men then undergo regular check-ups to manage potential side effects and see if cancer recurs so it can be treated quickly. The organisation of these check-ups varies across the country as it is not known which approach is best. The four different established approaches are (i) check-ups performed in hospital outpatients by the same team that provided treatment; (ii) patients seen regularly by their GP with hospital referral as necessary; (iii) planned shared care between general practice and hospital follow up; or (iv) patients supported to provide checks on themselves (self-care) and reaching out to a doctor or a nurse when required. This study will compare these options to establish which is best for patients and makes the best use of the NHS resources.",[113],"Prostate Cancer",[115,116,117,118,119,120,121,122,123],"prostate cancer","prostate cancer after curative treatment","prostate cancer follow up","propensity-matched cohort study","qualitative","discrete choice experiment","economic evaluation","routine data","patient survey","NOT_YET_RECRUITING","2026-04-13",{"date":127,"type":128},"2026-04-16","ACTUAL",{"date":130,"type":109},"2026-10",{"date":132,"type":109},"2027-07",{"name":5,"class":6},1]